医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Bond Labs Expands International Footprint

2013年09月18日 PM11:25
このエントリーをはてなブックマークに追加


 

OMAHA, Neb.

Bond Laboratories, Inc. (OTCBB:BNLB) (“Bond Labs”), an international provider of innovative and proprietary nutritional supplements for health conscious consumers, marketed primarily through its wholly owned operating division, NDS Nutrition Products (“NDS”), (www.ndsnutrition.com) today announced that the Company has received an initial purchase order to begin supplying product for GNC® franchise locations in India.

“We are thrilled, once again, to be able to announce continued international expansion as we prepare to launch in India. Our recent successful entrance into Singapore, Australia and Mexico further substantiates NDS as an established international premium brand. India, which has more than 66 GNC franchise locations, is an important market that provides both an incremental revenue opportunity as well as the potential to serve as a gateway for additional international expansion into the Middle East,” stated John S. Wilson, Bond Labs’ Chief Executive Officer. “International expansion remains a key strategic element of our long-term growth plan and the addition of India is another exciting step forward for the Company. Bond Labs now markets or is set to market its products in 13 countries. The GNC® international franchise system spans over 50 countries and our goal remains to have a presence in each and every one of them,” concluded Mr. Wilson.

About Bond Labs

Bond Laboratories is a manufacturer of innovative and proprietary nutritional supplements for health conscious consumers marketed primarily through NDS Nutrition Products (“NDS”) (www.ndsnutrition.com), a wholly owned operating division and, recently launched, Siren Labs (“Siren”) (www.sirenlabs.com). Together, NDS and Siren market approximately 60 different ultra-premium dietary supplements designed to promote sports nutrition, improved performance, weight loss and general health exclusively through GNC® franchises both domestically and internationally. Bond Labs is headquartered in Omaha, Nebraska. For more information, please visit www.bond-labs.com.

Forward-Looking Statement

Statements in this release that are forward looking involve known and unknown risks and uncertainties, which may cause the Company’s actual results in future periods to be materially different from any future performance that may be suggested in this news release. Such factors may include, but are not limited to: the ability of the Company to continue to grow revenue; the Company’s ability to continue to achieve positive cash flow given the Company’s existing and anticipated operating and other costs; and the outcome of the Company’s pending litigation with the U.S. Department of Labor and our former President alleging violations of certain unlawful employment practices in connection with his separation from the Company. Many of these risks and uncertainties are beyond the Company’s control. Reference is made to the discussion of risk factors detailed in The Company’s filings with the Securities and Exchange Commission, including its reports on Form 10-K and 10-Q. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the dates on which they are made.

CONTACT

for Bond Laboratories, Inc.
Surety Financial Group, LLC
Bruce
M. Weinstein, 410-833-2717

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表
  • Intercell USA Changes Name to Valneva USA, Inc. and Expands Commercial Presence
  • ADC Therapeutics präsentiert Zwischenergebnisse aus Phase-I-Studie zu neuartigem Antikörper-Wirkstoff-Konjugat ADCT-402
  • Bertin与Zymo Research宣布达成新的合作